StreetInsider.com News Articles

Form SCHEDULE 13G/A Arcturus Therapeutics Filed by: FEDERATED HERMES, INC.

Wed, 07 Oct 2026 07:17:00 -0400

si-local-file:///var/storage/secattach/20261007/27157940.html

Arcturus Therapeutics (ARCT) Reiterated at Overweight by Cantor Fitzgerald

Thu, 24 Sep 2026 07:17:20 -0400

Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating on Arcturus Therapeutics (NASDAQ: ARCT).

The analyst commented, "ARCT disclosed additional P2 data from its US study of ARCT-810 in ornithine transcarbamylase (OTC) deficiency (OTCD), a rare urea cycle disorder, and its next-gen OTCD candidate ARCT-2601. ARCT-810 is an IV-delivered mRNA therapy encoding OTC → MoA targets the underlying cause of the disease, which should drive efficacy. Next-gen candidate ARCT-2601 is optimized using LUNAR 2.0 (next-gen biodegradable lipid) to drive substantially higher protein expression → may allow for lower, less frequent dosing and greater efficacy. Next steps include expansion of the P2

Arcturus Therapeutics (ARCT) PT Lowered to $20 at BTIG

Thu, 24 Sep 2026 05:40:57 -0400

BTIG analyst Thomas Shrader lowered the price target on Arcturus Therapeutics (NASDAQ: ARCT) to $20.00 (from $23.00) while maintaining a Buy rating.

The analyst comments "Probably the most positive result we've ever seen that resulted in what looks like a soft reset. Soft meaning they aren't starting from scratch with early toxicology determinations based on the new lipid platform termed LUNAR 2.0. ARCT-810 certainly looks active with every patient benefitting - much as they did in the previous readout (note HERE). The degree of benefit remains somewhat hard to gauge as all these patients were considered controlled based on their concomitant

Arcturus Therapeutics (ARCT) PT Lowered to $20 at BTIG

Thu, 24 Sep 2026 05:40:57 -0400

BTIG analyst Thomas Shrader lowered the price target on Arcturus Therapeutics (NASDAQ: ARCT) to $20.00 (from $23.00) while maintaining a Buy rating.

Citi Upgrades Arcturus Therapeutics (ARCT) to Buy

Thu, 24 Sep 2026 02:44:59 -0400

Citi analyst Yigal Nochomovitz upgraded Arcturus Therapeutics (NASDAQ: ARCT) from Neutral to Buy with a price target of $20.00 (from $8.00).

For an analyst ratings summary and ratings history on Arcturus Therapeutics click here. For more ratings news on Arcturus Therapeutics click here.

Shares of Arcturus Therapeutics closed at $13.30 yesterday.

Form 8-K Arcturus Therapeutics For: Sep 23

Wed, 23 Sep 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260923/27096846.html

Arcturus shares Phase 2 OTC data, unveils new mRNA platform

Wed, 23 Sep 2026 16:01:54 -0400

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced interim Phase 2 results for its investigational mRNA therapeutic ARCT-810 in ornithine transcarbamylase (OTC) deficiency, and introduced LUNAR 2.0™, a next-generation mRNA delivery platform, according to a company statement.

In the ongoing Phase 2 study, ARCT-810 was described as generally safe and well tolerated. The drug reduced and/or maintained first morning fasting ammonia within the normal range, including during periods of increased protein intake by participants. Glutamine levels were also reduced, with participants at the 0.5 mg/kg dose level achieving mean glutamine values within the normal range during treatment. Weight gain was observed in

Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform

Wed, 23 Sep 2026 16:01:00 -0400

ARCT-810 generally safe and well tolerated, demonstrating encouraging activity across key urea cycle biomarkers in ongoing Phase 2 study

LUNAR 2.0™ produces greater than 30-fold higher protein expression in multiple NHP studies – unlocks new therapeutic opportunities

ARCT-2601, an OTC deficiency therapeutic candidate utilizing LUNAR 2.0™, to be integrated by YE 2026 into ongoing Phase 2 study as advised by the FDA

Arcturus to acquire myNEO, an AI discovery company, to improve mRNA design quality, accelerate innovation, and enhance target identification capability

Presentation at 4:30 p.m. ET today

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company,”

Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform

Wed, 23 Sep 2026 16:01:00 -0400

ARCT-810 generally safe and well tolerated, demonstrating encouraging activity across key urea cycle biomarkers in ongoing Phase 2 study

LUNAR 2.0™ produces greater than 30-fold higher protein expression in multiple NHP studies – unlocks new therapeutic opportunities

ARCT-2601, an OTC deficiency therapeutic candidate utilizing LUNAR 2.0™, to be integrated by YE 2026 into ongoing Phase 2 study as advised by the FDA

Arcturus to acquire myNEO, an AI discovery company, to improve mRNA design quality, accelerate innovation, and enhance target identification capability

Presentation at 4:30 p.m. ET today

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company,”

Arcturus Therapeutics to present Phase 2 OTC deficiency data

Fri, 18 Sep 2026 09:00:23 -0400

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced it will host a virtual presentation on September 23, 2026, at 4:30 p.m. ET to share Phase 2 clinical data from its ARCT-810 program for ornithine transcarbamylase (OTC) deficiency and provide an update on its mRNA liver therapeutics platform.

The company said it will issue a press release summarizing the presentation prior to the event. Marshall Summar, M.D., a former founding member and Executive Committee member of the NIH Urea Cycle Disorders (UCD) Consortium, will participate in the presentation.

ARCT-810 is an investigational intravenously administered mRNA therapeutic designed to express functional OTC enzyme in the

Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform

Fri, 18 Sep 2026 09:00:00 -0400

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will host a virtual presentation on Wednesday, September 23, 2026, at 4:30 p.m. ET.

The presentation will provide an overview of the ARCT-810 Phase 2 clinical program for Ornithine transcarbamylase (OTC) deficiency and Arcturus’ mRNA liver therapeutics platform. Prior to the call, the Company will issue a press release summarizing the presentation.

Marshall Summar, M.D., Former founding member and Executive Committee member of the NIH UCD Consortium,

Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform

Fri, 18 Sep 2026 09:00:00 -0400

Marshall Summar, M.D., Former founding member and Executive Committee member of the NIH UCD Consortium,

Form 8-K Arcturus Therapeutics For: Aug 25

Tue, 25 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260825/26970343.html

Form 8-K Arcturus Therapeutics For: Aug 25

Tue, 25 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260825/26970343.html

Arcturus Therapeutics (ARCT) Tops Q2 EPS by 21c

Thu, 06 Aug 2026 17:14:17 -0400

Arcturus Therapeutics (NASDAQ: ARCT) reported Q2 EPS of ($0.84), $0.21 better than the analyst estimate of ($1.05). Revenue for the quarter came in at $2.96 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

Form 10-Q Arcturus Therapeutics For: Jun 30

Thu, 06 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260806/26884450.html

Form 10-Q Arcturus Therapeutics For: Jun 30

Thu, 06 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260806/26884450.html

Form 8-K Arcturus Therapeutics For: Aug 06

Thu, 06 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260806/26883697.html

Form 8-K Arcturus Therapeutics For: Aug 06

Thu, 06 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260806/26883697.html

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress